Sol-Gel Technologies Ltd Dossier - Source-backed chat

Sol-Gel Technologies Ltd

SLGLNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.07

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $73.00Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $239M

Enterprise Value $228.8M

Shares Outstanding 2.8M diluted

Moat Rating None

Next Earnings Date19 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Sol-Gel Technologies Ltd. is a clinical-stage specialty dermatology company transitioning its focus toward rare and severe skin conditions, anchored by its lead asset SGT-610 (patidegib gel, 2%) for Gorlin syndrome. Following the strategic sale of its U.S. commercial rights for TWYNEO and EPSOLAY to Mayne Pharma for $16 million in 2025, and a highly successful $33.1 million oversubscribed equity offering in March 2026, the company has significantly extended its cash runway into the first quarter of 2028. This robust liquidity profile fully funds the company through its most critical near-term catalyst: the unblinding and reporting of pivotal Phase 3 top-line data for SGT-610 in Q4 2026. With a newly allowed U.S. patent extending SGT-610's exclusivity to 2044 and an estimated U.S. market potential of $400–$500 million annually, Sol-Gel represents a high-conviction biotech opportunity with asymmetric upside, supported by a solid financial foundation and established global licensing partnerships.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$110.00

Mean target$193.00

High · most bullish analyst$285.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$5.0020%

The Phase 3 trial for SGT-610 in Gorlin syndrome fails to show statistical significance or exhibits unexpected safety concerns in Q4 2026, leading to the discontinuation of the program. Following the previous clinical failure of SGT-210 in Darier disease in late 2025, the loss of the lead asset leaves the company solely reliant on its early-stage, low-cost feasibility studies and future international royalties from TWYNEO and EPSOLAY (which do not launch until 2027–2028). The stock experiences severe downward pressure, and the company is forced to seek dilutive financing or strategic alternatives as its cash runway depletes toward 2028.

Base CaseCentral scenario

$75.0050%

The Phase 3 trial for SGT-610 in Gorlin syndrome delivers positive top-line results in Q4 2026, demonstrating statistically significant prevention of new BCC lesions with a tolerable safety profile. Sol-Gel prepares and files an NDA with the FDA in 2027. The company's cash runway remains sufficient into Q1 2028, allowing it to advance pre-commercialization activities and initiate a proof-of-concept study in high-frequency BCC. Meanwhile, international partners progress toward scheduled launches of EPSOLAY (2027) and TWYNEO (2028) in licensed territories, keeping the company on track to achieve its projected annual royalty stream of $10 million by 2031.

Bull CaseUpside scenario

$110.0030%

The pivotal Phase 3 trial for SGT-610 in Gorlin syndrome meets all primary and secondary efficacy endpoints with an excellent safety profile in Q4 2026. The topical formulation demonstrates clear superiority over vehicle and avoids the severe systemic side effects associated with oral hedgehog inhibitors, positioning it as the first-ever approved preventative treatment for basal cell carcinomas in this population. Concurrently, Sol-Gel successfully initiates a Phase 3 trial for high-frequency BCC in 2027, doubling the drug's addressable market. Rapid regulatory approvals and strong commercial execution by global partners (such as Sun Pharma in India and Viatris in Australia/New Zealand) accelerate royalty streams, driving the stock toward the high-end analyst price targets.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Fully funded clinical runway into Q1 2028 following a $33.1 million oversubscribed underwritten offering in March 2026, eliminating near-term dilution risk before the major Q4 2026 catalyst.
Lead asset SGT-610 has orphan-drug and breakthrough-therapy designations from the FDA, targeting an underserved Gorlin syndrome market with an estimated U.S. potential of $400–$500 million annually.
Strong intellectual property protection secured by a U.S. Patent Office Notice of Allowance in May 2026, extending SGT-610's method-of-use patent protection until 2044.
Established global commercial footprint through out-licensing agreements for TWYNEO and EPSOLAY with top-tier partners (Sun Pharma, Viatris, Searchlight, Beimei), projected to deliver up to $10 million in annual royalties by 2031.

Key Investment Risks

High binary clinical trial risk associated with the upcoming Phase 3 top-line results for SGT-610 in Q4 2026.
Pipeline concentration risk, as the company discontinued its SGT-210 program for Darier disease in December 2025 due to a lack of efficacy differentiation in its Phase 1b study.
Geopolitical and security risks associated with the company's primary operations and headquarters being located in Ness Ziona, Israel.
Dependence on third-party collaborators and licensees for the successful commercialization, manufacturing, and marketing of TWYNEO and EPSOLAY in international markets.

Thesis Invalidation Triggers

Failure of SGT-610 to meet primary efficacy endpoints or demonstrate a favorable safety profile in the Phase 3 Gorlin syndrome trial in Q4 2026.
Significant delays in the regulatory filing or approval timelines for SGT-610 by the FDA.
Unexpected launch delays or poor commercial performance of TWYNEO and EPSOLAY by international partners, severely impacting the projected royalty streams.
Severe escalation of the regional security situation in Israel that disrupts corporate operations, clinical trial management, or key personnel retention.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.